Xenomics Inc. (XNOM) Transrenal Technology Shows Significant Promise in Molecular Diagnostic Applications
2/4/2009 2:35:49 PM
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Xenomics, Inc. (XNOM.PK), a developer of non-invasive next-generation molecular diagnostics, announced new data from a collaborative project with Dr. Warsof of Eastern Virginia Medical School, published on January 30th in the early online edition of the Clinical Chemistry. The data obtained in this new clinical study on detection of fetal gender by analysis of Transrenal DNA (Tr-DNA) isolated from maternal urine demonstrate 95.1% specificity in 173 pregnant women. Within a limited subset of urine samples, those collected in the first trimester, the test was 100% sensitive and 100% specific. These results were obtained when new proprietary methods of Tr-DNA isolation and analysis were applied for prenatal testing. Xenomics is currently developing its proprietary Tr-DNA/RNA technology for use in other tests, including early tumor detection and monitoring, diagnosis of infectious diseases, transplantation monitoring and other conditions.
comments powered by